Science 37 Holdings, Inc.

NasdaqCM:SNCE Stock Report

Market Cap: US$34.7m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Science 37 Holdings Future Growth

Future criteria checks 1/6

Science 37 Holdings is forecast to grow earnings and revenue by 66.7% and 17.5% per annum respectively while EPS is expected to grow by 67.9% per annum.

Key information

66.7%

Earnings growth rate

67.90%

EPS growth rate

Life Sciences earnings growth16.9%
Revenue growth rate17.5%
Future return on equityn/a
Analyst coverage

Low

Last updated30 Jan 2024

Recent future growth updates

Recent updates

Analysis Article • Dec 18

Science 37 Holdings, Inc. (NASDAQ:SNCE) Might Not Be As Mispriced As It Looks

With a price-to-sales (or "P/S") ratio of 0.5x Science 37 Holdings, Inc. ( NASDAQ:SNCE ) may be sending very bullish...
Analysis Article • Apr 17

Investors Continue Waiting On Sidelines For Science 37 Holdings, Inc. (NASDAQ:SNCE)

You may think that with a price-to-sales (or "P/S") ratio of 0.6x Science 37 Holdings, Inc. ( NASDAQ:SNCE ) is...
Seeking Alpha • Aug 18

Science 37, Syapse team for faster patient enrollment in cancer trials

Science 37 (NASDAQ:SNCE) Syapse said they are collaborating to deploy proprietary real-world data intelligence and analytics to help identify suitable patients for oncology clinical trials, thus helping speed up the enrollment process. "By partnering with Syapse, we will have the ability to tap into advanced data-intelligence capabilities to make effective trial identification and recruitment a reality for patients and sponsors," said Science 37 Chief Medical Officer Jonathan Cotliar.
Seeking Alpha • Aug 11

Science 37 reports Q2 mixed earnings; narrows FY22 guidance

Science 37 press release (NASDAQ:SNCE): Q2 GAAP EPS of -$0.05 beats by $0.19. Revenue of $19.3M (+53.8% Y/Y) misses by $0.2M. Net bookings were $25.4M for the quarter ended June 30, 2022, compared to $44.1M for the same period in 2021. Adjusted EBITDA was -$16.5M for the quarter ended June 30, 2022, compared to -$5.4M in the same period in 2021.  Science 37 is providing revenue guidance of $76 million to $86 million vs. consensus of $92.24M and adjusted EBITDA guidance of $(65) million to $(69) million for the fiscal year ending December 31, 2022.
Analysis Article • May 13

Results: Science 37 Holdings, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

It's been a sad week for Science 37 Holdings, Inc. ( NASDAQ:SNCE ), who've watched their investment drop 20% to US$3.03...
Analysis Article • Apr 11

Science 37 Holdings (NASDAQ:SNCE) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Jan 02

Science 37: Pioneering Decentralized Clinical Trials

Science 37 pioneered the concept of decentralized clinical trials. The Covid-19 pandemic drove more demand for DCTs. The Company is a leader in its niche DCT market worth over $60 billion.
Analysis Article • Nov 04

We Think Science 37 Holdings (NASDAQ:SNCE) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Earnings and Revenue Growth Forecasts

NasdaqCM:SNCE - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026953-18303
12/31/202575-25-2833
12/31/202463-38-44-94
12/31/202358-73-81-464
9/30/202360-125-74-48N/A
6/30/202362-134-84-58N/A
3/31/202366-121-98-67N/A
12/31/202270-51-107-75N/A
9/30/202275-50-115-82N/A
6/30/202273-41-108-78N/A
3/31/202266-43-83-57N/A
12/31/202160-94-57-36N/A
9/30/202150-42-37-23N/A
6/30/202143-35-33-23N/A
3/31/202133-33-33-26N/A
12/31/202024-32-32-25N/A
12/31/201914-18-20-16N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SNCE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SNCE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SNCE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SNCE's revenue (17.5% per year) is forecast to grow faster than the US market (8.1% per year).

High Growth Revenue: SNCE's revenue (17.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if SNCE's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/03/11 13:43
End of Day Share Price 2024/03/11 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Science 37 Holdings, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Eric ColdwellBaird
Matthew HewittCraig-Hallum Capital Group LLC
Frank TakkinenLake Street Capital Markets, LLC